Migration of RCC cells in the presence of a CCR2 antagonist or neutralizing CCL2 antibody was also markedly decreased compared with control cells and enhanced by supplemented CCL2 (128, 146). The gene discussed is CCR2; the disease is renal cell carcinoma.